TG Therapeutics logo

TG TherapeuticsNASDAQ: TGTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 May 2010

Next earnings report:

01 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.90 B
-25%vs. 3y high
87%vs. sector
-98%vs. 3y high
70%vs. sector
-88%vs. 3y high
97%vs. sector
-99%vs. 3y high
77%vs. sector

Price

pre-market | 17 min ago
$25.22+$0.07(+0.28%)

Dividend

No data over the past 3 years
$73.47 M$81.71 M
$73.47 M$6.88 M

Analysts recommendations

Institutional Ownership

TGTX Latest News

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
globenewswire.com01 November 2024 Sentiment: -

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S.

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
globenewswire.com18 September 2024 Sentiment: POSITIVE

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
globenewswire.com05 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 – 20, 2024, in Copenhagen, Denmark. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2024 Programme. Details of the presentations are outlined below.

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
seekingalpha.com07 August 2024 Sentiment: POSITIVE

TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.

TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
globenewswire.com05 August 2024 Sentiment: POSITIVE

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S.

TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance
seekingalpha.com30 July 2024 Sentiment: POSITIVE

Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with less room for significant increases in the full-year guidance after a large increase in May. New patient starts should exceed 1,400 in the second quarter, and we should hear management comments on how they are preparing for the launch of subcutaneous Ocrevus in Q4.

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
globenewswire.com31 May 2024 Sentiment: POSITIVE

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links.

TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
Seeking Alpha02 May 2024 Sentiment: POSITIVE

TG Therapeutics, Inc. (NASDAQ:TGTX) will be holding its Q1 2024 Earnings Conference Call on May 1, 2024 at 8:30 AM ET. Key participants include Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Conference call participants include analysts from Evercore ISI, H.C. Wainwright, Jefferies, Ladenburg Thalmann, and B.

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research01 May 2024 Sentiment: NEGATIVE

TG Therapeutics reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, compared to a loss of $0.28 per share in the same quarter last year.

  • 1(current)
  • 2
  • 3

What type of business is TG Therapeutics?

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

What sector is TG Therapeutics in?

TG Therapeutics is in the Healthcare sector

What industry is TG Therapeutics in?

TG Therapeutics is in the Biotechnology industry

What country is TG Therapeutics from?

TG Therapeutics is headquartered in United States

When did TG Therapeutics go public?

TG Therapeutics initial public offering (IPO) was on 03 May 2010

What is TG Therapeutics website?

https://www.tgtherapeutics.com

Is TG Therapeutics in the S&P 500?

No, TG Therapeutics is not included in the S&P 500 index

Is TG Therapeutics in the NASDAQ 100?

No, TG Therapeutics is not included in the NASDAQ 100 index

Is TG Therapeutics in the Dow Jones?

No, TG Therapeutics is not included in the Dow Jones index

When was TG Therapeutics the previous earnings report?

No data

When does TG Therapeutics earnings report?

The next expected earnings date for TG Therapeutics is 01 November 2024